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ABSTRACT
Hepatitis C virus (HCV) infection is a global problem that causes liver disease and hepatocellular carcinoma. Although the
current standard treatment provided a significant improvement on response rate with sustain virology response more than
90%, however, the high cost was remaining limited access to this therapy, resistance emergence and serious side effects
which provide the necessities to find the new anti-HCV agents. The current study, we evaluated the ethanol extract of Phyllanthus
niruri for its anti-HCV activities. Anti-HCV activity was determined by in vitro culture cells of Huh 7it. Anti-HCV activity
of P. niruri extract revealed strong inhibition against HCV with IC50 values of 4.14 µg/mL and yield stronger activity in the
entry step of the HCV life cycle. Moreover, the P. niruri extract enhanced anti-HCV activity of simeprevir (NS3 protease
inhibitor) with increase the activity up to 4-fold compared to a single treatment of simeprevir. Docking analysis was performed
to predict the interaction phyllanthin and hypophyllantin, known compounds of P. niruri against HCV receptor. Both of
phyllantin and hypophyllantin were mediated a strong interaction with 4GAG, a protein that involved in entry step of HCV.
These results suggested that the ethanol extract of P. niruri may be good candidates for the development of anti-HCV drugs.
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INTRODUCTION
Hepatitis C virus (HCV) infection is a serious
health problem and a potential cause of substantial
morbidity and mortality. The infections could lead
to chronic liver diseases, such as hepatitis, liver
disorder and hepatocellular carcinoma. The pre-
valence of HCV infection is infected around 71
million people worldwide (The Polaris Observatory
HCV Collaborators; European Union HCV Collabo-
rators). There is no vaccine of HCV that have been
developed. The current treatment of HCV used oral
IFN-free regimen, includes a combination of
direct-acting antiviral agents (DAAs), is capable
of providing a sustained virological response (SVR)
for more than 90% (Gonzalez-Grande et al., 2016).
However, the viral resistance issue, side effects,
and economical view due to the high cost of current
treatment agents remained the necessities to
develop complementary and/or alternative drugs
for the treatment of HCV.
Medicinal plants are rich with many chemical
substances such as flavonoids, terpenoids, lignans,
polyphenolics, coumarins, saponins, furyl com-
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pounds, alkaloids, polylines, proteins and peptides,
that have been reported to possess various
bioactivities including antiviral. Those compounds
and their derivatives have been determined to
possess anti-HCV activities that have promise for
development into anti-HCV agents (Calland et al.,
2012; Jassim & Naji 2003; Khachatoorian et al.,
2012; Wahyuni et al., 2016). Alkaloid and coumarin
compounds of R. angustifolia, pseudane IX and
chalepin, respectively, possess a strong inhibition
against HCV (Wahyuni et al., 2014). Honokiol, a
lignan compound from Magnolia officinalis,
reported inhibiting HCV with an IC50 value of 4.5
µM (Lan et al., 2012), while a lignan compound
from Swietenia macrophylla, 3-hydroxy caruilignan
C, reduced HCV protein and RNA level with IC50
value of 10.5 µM (Wu et al., 2012).
Phyllanthus niruri belongs to the family of
Euphorbiaceae and is widely distributed in tropical
and subtropical regions. It has been traditionally
used for many kinds of disease including to reduce
fever, treat jaundice and liver diseases. The various
species of Phyllanthus family such as the P. amarus,
P. niruri, P. urinaria and P. orbicularis have been
reported to demonstrate potential inhibitory effect
against a broad spectrum of viruses. They showed
to possess potential inhibition in human immuno-
deficiency virus (HIV), herpes simplex virus (HSV)
and hepatitis B virus (HBV) (Forero et al., 2008;
Tan et al., 2013). Phyllanthus amarus has been
demonstrated to have potential inhibition on HCV
replication (Ravikumar et al., 2011). Nirtetralin B,
a lignan isolated compounds of P. niruri exhibited
to suppress the secretion of the HBV antigens (Liu
et al., 2014). Other lignan compounds, phyllanthin
and hypophyllanthin were reported to mediate
anti-viral activities against hepatitis B virus and
human immunodeficiency virus (HIV) (Bagalkotkar
et al., 2006; Venkateswaran et al., 1987). This study
was evaluated the anti-HCV activity of P. niruri
by in vitro culture cells and further analyzed the
mechanism of action. To predict the mechanism of
known compounds, docking analysis of phyllanthin
and hypophyllanthin was done to evaluate the
interaction with protein in Protein Data Base
(www.rcsb.org) that involve in HCV activity.
MATERIALS AND METHODS
Extraction and sample preparation
The herb of P. niruri was harvested from Bandung,
West Java, Indonesia. The plant was verified by a
licensed botanist of Botanical garden, Purwodadi,
Indonesia. The dried powder of the herb was pulverized
and extracted by maceration method with 96% of
ethanol. The obtained filtrates were evaporated to yield
the ethanolic extracts of P. niruri. The stock solution
was prepared by dissolving the extract in dimethyl
sulfoxide (DMSO) to obtain a stock concentration of
100 mg/mL. Serial dilutions of extracts were prepared
to yield the concentrations of extracts 100, 50, 10, 1,
0.1 and 0.01 µg/mL.
Cells and Hepatitis C virus preparation
Huh7it cells (Aoki et al., 2014) were cultivated
in Dulbeco’s Modified Eagle Medium (GIBCO
Invitrogen, Carlsbad, CS, USA) supplemented with
10% Fetal Bovine Serum (Biowest, Nualle, France),
0.15 mg/mL Kanamycin (Sigma-Aldrich, St. Louis,
MO, USA) and non-essential amino acids (GIBCO-
Invitrogen) in 5% CO2 at 37°C. The culture cells
were cultivated and maintained by periodically
re-feeding with a new medium. The adapted HCV
variant was propagated in Huh7it (Apriyanto et al.,
2016). Culture supernatant from the infected cells
was collected at day 2 and day 5 post-infection and
concentrated using Amicon Ultra centrifugal filter
unit. Virus titers were determined for antiviral assay
(Hafid et al., 2017).
Anti-Hepatitis C activity assay
Antiviral activity assay was conducted as
described previously (Aoki et al., 2014; Hafid et al.,
2017; Wahyuni et al., 2013; Wahyuni et al., 2014).
Huh7it cells (5.4 × 104) were seeded for 24 hours.
The HCV at the multiplication of infection (MOI)
of 0.1 in the presence of different concentrations
of the sample were inoculated to the culture cells.
The cells were treated with a serial concentration of
P. niruri extract. The mixture of extract and virus
was incubated for 2 hours for virus absorption and
the cells were rinsed with the medium. Infected-cells
were further incubated in the medium containing
the same concentration of sample for 46 hours.
Mode of action analysis was performed by time-
of-addition experiments with three series of
experiments. First, the culture was treated with the
extract both in pre- and post- inoculation. Second,
the culture was only treated with the extract at
inoculation steps (2 hours). The third extract was
added only after inoculation to examine the action
of a substance in the post-entry steps of the HCV
life cycle. Culture supernatants were collected for
virus titration. The percentage inhibitory was
determined and the 50% inhibitory effect (IC50) was
calculated by SPSS probit analysis (Wahyuni et al.,
2013; Wahyuni et al., 2014). Combination treatment
to evaluate the effect of P. niruri extract was done
by added the extract to the serial concentration of
simeprevir, the NS3 protein inhibitor.
Virus titration and immunostaining
Huh7it-1 cells (2 × 104 cells/well) were seeded in
a 96-well plate and incubated for 24 hours. Virus
supernatants were diluted in the medium and
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inoculated onto the Huh7it culture cells and incubated
for 4 hours. After virus absorption, the cells were
cultured with medium containing 0.4%
methylcellulose (Sigma-Aldrich) following 41 hours
incubation. Infected cells were analyzed with
immunostaining using anti-HCV patient anti-serum
(250-time dilution on 2% BlockAce/1%BSA/PBS) and
HRP-goat antihuman Ig antibody (300× on 2%
lockAce/1%BSA/PBS). The HCV antigen positive
cells were visualized with Metal Enhanced DAB
substrate kits (Thermo Fisher Scientific, Rockford,
USA). The infected cells were counted under
microscopes and calculated the percentage inhibition.
Cytotoxicity analysis
The cytotoxicity analysis was conducted to
determine whether the extract mediated any
cytotoxicity effects. MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) assay was
done by inoculating 100, 50, 10, 1, 0.1 and 0.01
µg/mL of extract in 96 wells plate culture cells which
have seeded for 24 hours. After 48 h incubation, the
medium was replaced with MTT reagent containing
medium and incubated for 4 hours. Absorbance
sample was evaluated under a microplate reader at
450 and 600 nm, which is correlated with the amount
of cell viability. The percentage of cell toxicity was
calculated by comparing with untreated cells and
further determine its 50% cytotoxic concentration
(CC50) values (Apriyanto et al., 2016).
Docking analysis of phyllanthin and hypo-
phyllanthin
The ligand was prepared by making 2D and 3D
structures of the phyllanthin and hypophyllanthin
using ChemBioOffice program Ultra 11.0 and its
energy was minimized using MMF94. The docking
analysis continued by Molegro Virtual Docking
ver 5.5 program Ver 5.5, resulted in rerank score
describing the minimal energy by the ligand in
interaction with the receptor.
RESULTS
Anti-hepatitis C virus activity and cytotoxicity
assay of Phyllanthus niruri extract
Ethanolic extract of P. niruri was examined for
antiviral activities against hepatitis C virus JFH1. The
result showed that P. niruri possesses potential
inhibition against hepatitis C virus without any
cytotoxicity. Dose dependent on percentage inhibition
and cell viability of P. niruri was shown in Table 1.
The 50% inhibitory concentrations (IC50) was
determined by probit analysis and yield the IC50 value
of 4.14 µg/mL without any cytotoxic effect with the
50% cytotoxic concentrations (CC50) >100 µg/ml and
selectivity indexes (SI: CC50/IC50) > 24.2.
Mode of Action analysis of Phyllanthus niruri
extract
To evaluate that actions of extract in the HCV life
cycle, mode of action analysis of P. niruri extract was
performed. The three parallel experiments were exerted,
first the cells culture were treated with the plant extract
in both pre- and post-inoculation, second cells were
treated with extract only during inoculation to
determine the action of extract in the entry step and
third, cells were treated only post-inoculation to
evaluate the action of extract in the post entry step.
Pre-inoculation treatment obtained higher inhibition
than post-inoculation treatment. It indicated that the
extract of P. niruri mainly inhibits at the entry step.
The percentage of HCV inhibition in the entry step
was 70% while post-entry step was less than 50%
(Figure 1). This result indicated that the mechanism of
action of P. niruri was predicted in the attachment
with some host receptor of entry to the host cell via
endocytosis process.
Table 1. Dose dependent on percentage inhibition and cell
viability of Phyllanthus niruri
Concentration % HCV % Cell
(µg/mL) inhibition viability
0.01 13.3 ± 4.7* 99.8 ± 0.4
0.1 22.5 ± 4.1 99.0 ± 0.9
1 25.5 ± 5.8 98.8 ± 1.2
10 44.3 ± 3.3 98.7 ± 1.2
50 88.0 ± 5.1 98.7 ± 1.3
100 100.0 ± 0.0 98.3 ± 1.5
* Data represent means ± SEM of data from three independent
experiments.
Fig. 1. Extract of Phyllanthus niruri (30 µg/ml) inhibits
HCV mainly in the entry step. Three kinds of experiments
were done in parallel. Entry: infected-culture cells were
treated with extract only in pre-inoculation, Post entry:
infected-culture cells were treated only post-inoculation,
both: infected-culture cells were treated with extract in the
pre-and post-inoculation. The percentage HCV inhibition,
both: 88%, entry: 70%:43%. Data represent means ± SEM
of data from three independent experiments.
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Fig. 3. Reduction of HCV NS3 protein level by Phyllanthus
niruri extract. Huh 7.5it cells were infected with HCV and
treated with ethanol extract of Phyllanthus niruri (50 and
75 mg/ml) and the untreated control (CTR) were subjected
to western blot analysis. β-actin served as an internal control
to verify equal amounts of sample loading.
Fig. 2. Extract of Phyllanthus niruri (25 µg/mL) enhanced
anti-hepatitis C activity of simeprevir. In parallel, culture
cells were treated with a serial concentration of simeprevir
only and the other was treated with a combination of
simeprevir and extract. Data represent means ± SEM of
data from three independent experiments.
Combination treatment of Phyllanthus niruri
extract and simeprevir (NS3 protease inhibitor)
Simeprevir is an antiviral drug that acts to
inhibit NS3 protein. Combination treatment by
adding 25 µg/mL of P. niruri extract was obtained
increasing HCV inhibition (Figure 2). The potency
of combination treatment was increased in 4-fold
with the IC50 value 3.54 nM ± 0.05, while the IC50
value of simeprevir single treatment was 11.23 nM
± 0.36. P. niruri extract showed to reduce HCV NS3
protein level under western blot analysis (Figure 3).
Docking analysis of known compounds from
Phyllanthus niruri
Phyllanthin and hypophyllanthin are known as
isolated compounds from P. niruri. To predict the
interaction of those compounds docking analysis
was performed. Several proteins from Protein Data
Base (www.rcsb.org) were evaluated to examine their
interaction with Phyllanthin and hypophyllanthin.
The result demonstrated a strong interaction
between phyllanthin and hypophyllanthin with
4GAG. The rerank score value of phyllanthin and
hypophyllanthin were -110.125 and -88.5645 kcal/
mol, respectively, while the rerank score of standard
ligands was -45.0229 kcal/mol. This result indicated
the strong interaction between phyllanthin and
hypophyllanthin to the 4GAG receptor. The receptor
of 4GAG was reported to be a protein that involves
in the entry step of HCV, neutralizing antibody
AP33 in complex with E2 epitope (Colpitts and
Baumert 2016; Zhu et al., 2014).
The hydrogen bonding and steric van der walls
interaction were involved in the interaction between
compounds to the receptor. Hydrogen bonding of
phyllanthin with His 164 and Gln 42, and the steric
van der walls between phyllanthin with, Asp 167,
Vall 163, His 164, Gln42, Lys39, Pro40 and Gly41
contributed the binding interaction of 4GAG and
phyllanthin (Figure 4A). Hypophyllanthin revealed
weaker interaction than phyllanthin with hydrogen
binding to His 164 and steric van der walls-bond
to Asp167, Val163, His164 and Thr165 (Figure 4B).
While the standard ligand revealed hydrogen
binding to His 164 and Asp 167 and steric van der
walls to Asp 167. The interaction of phyllanthin and
4GAG was clearly described in the 3D profile
(Figure 5).
DISCUSSION
Medicinal plants and many natural sources are rich
with chemical substances that responsible in many
bioactivities including antiviral. We previously
summarized potential plants that have anti-HCV
activity (Wahyuni et al., 2016). Our current study
reported anti-HCV activities of P. niruri against
HCV JFH1. Plant with the genus of Phyllanthus was
reported to have many bioactivities such as
antimicrobial, antioxidant, anticancer, anti-
inflammatory, anti-plasmodial, hepatoprotective
and antiviral (Calixto et al., 1998; Kaur et al.,
2017). This study found that ethanolic extract of
P. niruri inhibited HCV with IC50 value of 4.14
µg/mL without showing cytotoxicity. The extract of
P. niruri may interfere with the inhibition effect
in the several steps of the HCV life cycle. Further
study to examine the effect of P. niruri extract in
the entry or post-entry step of the HCV life cycle
was evaluated by mode-of-action analysis. The
result was described that P. niruri possesses a
dominant inhibition in the entry steps of the HCV
life cycle (Figure 1). The steps in HCV life cycle
include entry into the host cells, uncoating and
replication of the viral genome, translation of virus
proteins, and assembly and release of the virion
(Lindenbach et al., 2005; Ploss & Dubuisson 2012).
In the attachment/entry step, the HCV lipoviral
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Fig. 4. Hydrogen bond interaction (dashed blue-line) and Steric-Van der Walls bond interaction (dashed
red-line) between Standard Ligand and A) phyllanthin, (B) hypophyllanthin, on the active site of
HCV protein (4GAG.pdb).
Fig. 5. The 3D profile of docking interaction of phyllanthin (green color) with 4GAG protein.
particles attach to the cell surface and interact
with glycosaminoglycans (GAG), low-density
lipoprotein receptor (LDLR), scavenger receptor
class B type 1 (SRB1) and CD81. Then, the viral
interaction with CLDN1 results in internalization
of the virus via clathrin-mediated endocytosis.
Following acidification of the endosome and
subsequent fusion of viral and endosomal mem-
branes, the viral genome is released into the
cytoplasm. On the other hand, the lateral movement
of HCV-CD81 causes the transmission of the virus
by cell-to-cell contact (Lindenbach & Rice, 2013;
Zeisel et al., 2015).
Combination treatment was done by adding the
extract of P. niruri to the serial concentrations of
simeprevir, an NS3 protein inhibitor which acts
in the replication step of HCV. The addition of
P. niruri extract increased anti-HCV activity of
simeprevir in almost 4-fold with the IC50 value 3.54
nM ± 0.05, while the IC50 value of simeprevir single
treatment was 11.23 nM ± 0.36. These results
indicated that P. niruri extract enhanced the anti-
HCV activity of simeprevir. P. niruri was demon-
strated to possess a reduction effect on HCV NS3
protease level at the dose of 50 µg/mL of extract
(Figure 3) which indicated that P. niruri may also
involve in the replication step of HCV life cycle.
The various metabolites in the plants do
contribute to anti-HCV activities such as lignan,
terpenoids, flavonoids, alkaloid, tannin and steroid
(Geethangili & Ding 2018; Kaur et al., 2017).
Niranthin and hinokinin isolated compounds from
P. amarus have strong anti-hepatitis B activities
while corilagin was reported to block HCV NS3
protease and NS5B RNA-dependent-RNA-
polymerase (Huang et al., 2003; Reddy et al., 2018).
P. niruri possessed various compounds, such as
quercetin, niruriflavone, rutin, ellagic acid,
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phyllanthin, hypophyllanthin, niranthin, lintetralin,
phyltetralin, etc. (Bagalkotkar et al., 2006).
Phyllanthin and hypophyllanthin are the lignan
compounds that were reported as major compounds
of P. niruri (Calixto et al., 1998). To predict the
mechanism-of-action of phyllanthin and hypo-
phyllanthin to the HCV receptor, docking analysis
was done by Molegro Virtual Docking ver 5.5
program. Phyllanthin and hypophyllanthin possess
smaller re-rank value to compare to the ligand, it
indicated the stronger interaction to 4GAG receptor,
a protein that involves in the entry step of HCV,
neutralizing antibody AP33 in complex with E2
epitope (Colpitts & Baumert 2016). The interaction
of phyllathin and hypophyllanthin to the receptor
4GAG resulting in an entry inhibition of HCV to the
hepatocyte cells. The interaction of phyllanthin
more stable than hypophyllanthin. Thus, it predicted
to have higher biological activity.
CONCLUSION
These results obtained strong activity of P. niruri
extract against the hepatitis C virus that showed
stronger inhibition in the entry step and enhances
the activity of simeprevir. Phyllanthin and hypo-
phyllanthin, known compounds of P. niruri
predicted to possess strong interaction with 4GAG,
a protein receptor that involves in the entry step of
HCV. These results suggest that P. niruri would be
a good candidate to develop anti-hepatitis C agents.
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